German pharma industry slams delay to orphan drug reimbursement
This article was originally published in SRA
Executive Summary
A recent Decision by the German joint federal committee (G-BA) to impose a second assessment procedure where orphan drugs are being considered for reimbursement, has been fiercely condemned by the pharmaceutical industry association, BPI. The association fears that long-winded assessment mechanism employed by the G-BA – a senior regulatory body that undertakes, among other things, health technology assessment for reimbursement purposes – will simply delay the provision of the drugs to the chronically ill.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: